Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
35.04 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1.039 | 4.013 | 4.737 | 1.078 | 0.071 | 1.193 | 2.428 | 2.045 | 0.589 |
| Cost of Revenue
| 0 | 0 | 1.389 | 1.262 | 56.998 | 1.113 | 24.479 | 9.233 | 5.1 |
| Gross Profit
| 1.039 | 4.013 | 3.348 | -0.184 | -56.927 | 0.08 | -22.051 | -7.188 | -4.511 |
| Gross Profit Ratio
| 1 | 1 | 0.707 | -0.171 | -801.789 | 0.067 | -9.082 | -3.515 | -7.659 |
| Reseach & Development Expenses
| 240.156 | 168.527 | 130.225 | 84.255 | 56.998 | 41.506 | 24.479 | 9.233 | 5.1 |
| General & Administrative Expenses
| 99.737 | 58.094 | 42.394 | 24.525 | 18.026 | 13.519 | 6.659 | 1.939 | 1.533 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 99.737 | 58.094 | 42.394 | 24.525 | 18.026 | 13.519 | 6.659 | 1.939 | 1.533 |
| Other Expenses
| 0 | 0 | 4.974 | 0.061 | -0.071 | -1.193 | 1.595 | -0.048 | -0.001 |
| Operating Expenses
| 339.893 | 226.621 | 172.619 | 108.78 | 74.953 | 53.832 | 28.71 | 9.127 | 6.044 |
| Operating Income
| -338.854 | -222.608 | -167.882 | -107.702 | -74.953 | -53.832 | -28.71 | -9.127 | -6.044 |
| Operating Income Ratio
| -326.135 | -55.472 | -35.441 | -99.909 | -1,055.676 | -45.123 | -11.825 | -4.463 | -10.261 |
| Total Other Income Expenses Net
| 40.446 | 8.079 | 3.964 | 0.061 | 1.141 | 3.41 | 1.595 | -0.03 | 0.025 |
| Income Before Tax
| -298.408 | -214.529 | -163.918 | -107.641 | -73.812 | -50.422 | -27.115 | -9.157 | -6.019 |
| Income Before Tax Ratio
| -287.207 | -53.459 | -34.604 | -99.853 | -1,039.606 | -42.265 | -11.168 | -4.478 | -10.219 |
| Income Tax Expense
| 0 | 0 | -3.964 | -0.922 | -0.948 | -0.887 | 1.595 | -0.04 | 0.01 |
| Net Income
| -298.408 | -214.529 | -159.954 | -106.719 | -72.864 | -49.535 | -27.115 | -9.157 | -6.019 |
| Net Income Ratio
| -287.207 | -53.459 | -33.767 | -98.997 | -1,026.254 | -41.521 | -11.168 | -4.478 | -10.219 |
| EPS
| -3.69 | -3.69 | -3.08 | -2.78 | -2.39 | -2.05 | -2.23 | -0.66 | -0.43 |
| EPS Diluted
| -3.69 | -3.69 | -3.08 | -2.78 | -2.39 | -2.05 | -2.23 | -0.66 | -0.43 |
| EBITDA
| -338.854 | -221.51 | -166.899 | -106.78 | -72.586 | -49.309 | -28.239 | -8.999 | -5.952 |
| EBITDA Ratio
| -326.135 | -55.198 | -35.441 | -99.909 | -1,055.676 | -45.123 | -11.825 | -4.411 | -10.044 |